drugset / Trial / NCT02474134

Comparison Study of PF530 and Betaferon in Healthy Subjects

NCT02474134

Phase 1 Completed 12 enrolled Pfenex, Inc
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the safety, tolerability, and blood levels of two interferon beta-1b products, Betaferon and PF530, in healthy volunteers.

Timeline

Start
2015-03
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1b Protein / enzyme biologic 0.25 mg Subcutaneous
Subject PF530 Unknown 0.25 mg Subcutaneous

Indications